AbbVie Completes Acquisition of Apogee Therapeutics
PRNewswire (Thu, 3-Sep 8:35 AM ET)
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
Globe Newswire (Mon, 10-Aug 7:00 AM ET)
Are DSGR, AVB, SLP, APGE Obtaining Fair Deals for their Shareholders?
PRNewswire (Fri, 31-Jul 11:02 AM ET)
Business Wire (Thu, 30-Jul 12:07 PM ET)
Globe Newswire (Tue, 14-Jul 6:55 PM ET)
PRNewswire (Tue, 14-Jul 4:00 PM ET)
Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 6-Jul 8:02 PM ET)
PRNewswire (Mon, 6-Jul 2:18 PM ET)
Are APGE, INVE, CBAN, FSRL Obtaining Fair Deals for their Shareholders?
PRNewswire (Thu, 2-Jul 3:38 PM ET)
Globe Newswire (Thu, 2-Jul 5:34 AM ET)
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Apogee Therapeutics trades on the NASDAQ stock market under the symbol APGE.
As of September 8, 2026, APGE stock price was flat at $135.07 with million shares trading.
APGE has a beta of -0.96, meaning it tends to be less sensitive to market movements. APGE has a correlation of 0.04 to the broad based SPY ETF.
APGE has a market cap of $10.21 billion. This is considered a Large Cap stock.
Last quarter Apogee Therapeutics reported $0 in Revenue and -$1.14 earnings per share. This fell short of revenue expectation by $-10 million and missed earnings estimates by -$.15.
In the last 3 years, APGE traded as high as $135.09 and as low as $14.19.
The top ETF exchange traded funds that APGE belongs to (by Net Assets): VTI, VB, VXF, VBR, VTWO.
APGE has outperformed the market in the last year with a price return of +263.8% while the SPY ETF gained +19.2%. APGE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +48.6% and +0.2%, respectively, while the SPY returned +1.4% and 0.0%, respectively.
APGE support price is $134.97 and resistance is $135.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APGE shares will trade within this expected range on the day.
